Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 3/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | F12 | P00748 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30151959 | 0.82 | SYK (0.34) | GAAHDAC6SMN1; SMN2NPC1RAB9A | |
| SCHEMBL8720225 | 0.79 | CDK2 (0.59) | CYP1A2CYP3A4GAACYP2C19BRD4 | |
| SCHEMBL10644616 | 0.79 | ALDH1A1 (0.56) | GAAMAPK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL5694143 | 0.78 | MEN1 (0.51) | CYP1A2CYP3A4GAACYP2C19BRD4 | |
| SCHEMBL5492353 | 0.78 | GAA (0.57) | GAAADORA1ADORA3ADORA2ASMN1; SMN2 | |
| SCHEMBL5196384 | 0.77 | GDA (0.40) | CYP1A2CYP2C19ADORA1ADORA3SMN1; SMN2 | |
| SCHEMBL5017650 | 0.77 | NPC1 (0.55) | CYP1A2CYP3A4GAACYP2C19F2 | |
| SCHEMBL8121389 | 0.76 | BRD4 (0.51) | CYP1A2BRD4F2ADORA1F12 | |
| SCHEMBL31060745 | 0.76 | NPC1 (0.58) | CYP1A2CYP3A4GAACYP2C19ADORA1 | |
| SCHEMBL6307534 | 0.76 | NPC1 (0.58) | CYP1A2CYP3A4GAACYP2C19ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5654255-A | MIXTURE OF A N,N-DIMETHYLPIPERIDINIUM SALT, HEXITOL AND CYTOKININ; COTTON PLANTS | BASF CORPORATION (US) | 1997-08-05 | — | — | US | claimed |
| US-7634870-B1 | Cytokinin enhancement of cotton | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2009-12-22 | — | — | US | disclosed |
| EP-1108724-B1 | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules | SIRNA THERAPEUTICS INC (US) | 2007-09-19 | — | — | EP | disclosed |
| US-6972330-B2 | Contacting N4-acetyl-5',3'-di-O-acetyl-2'-O- methyl cytidine with Lewis acid to form 2'-)-methyladenosine nucleoside which is converted to phosphoramidite | SIRNA THERAPEUTICS, INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20030204078-A1 | Chemical synthesis of methoxy nucleosides | RIBOZYME PHARMACEUTICALS, INC. | 2003-10-30 | — | — | US | disclosed |
| EP-1108724-A2 | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-06-20 | — | — | EP | disclosed |
| EP-0886641-A2 | SYNTHESIS OF METHOXY NUCLEOSIDES AND ENZYMATIC NUCLEIC ACID MOLECULES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-12-30 | — | — | EP | disclosed |
| WO-1997026270-A2 | SYNTHESIS OF METHOXY NUCLEOSIDES AND ENZYMATIC NUCLEIC ACID MOLECULES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030204078-A1 | Chemical synthesis of methoxy nucleosides | UMPS, PNP, NUDT1 | CYP1A2 671/4885CYP3A4 524/4885GAA 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.